Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac

See also
Status	Clinical Trial	Phase
Completed	`NCT02880137` - Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy	Phase 4
Terminated	`NCT01848301` - Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation	Phase 1
Terminated	`NCT01278745` - Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation	Phase 2
Withdrawn	`NCT01812434` - Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients	N/A
Withdrawn	`NCT01305382` - Noninvasive Evaluation of Cardiac Allograft Vasculopathy	N/A
Recruiting	`NCT05826444` - Microvascular Cardiac Allograft Vasculopathy Trial
Suspended	`NCT05756088` - Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
Completed	`NCT02013037` - The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation	Phase 3
Withdrawn	`NCT01305395` - Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients	N/A
Withdrawn	`NCT01157949` - A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)	Phase 3
Enrolling by invitation	`NCT06147271` - Impact of SGLT2 Inhibitors in Heart Transplant Recipients	Phase 2
Recruiting	`NCT04193306` - Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients	Phase 4
Recruiting	`NCT02798731` - Physiologic Assessment of Microvascular Function in Heart Transplant Patients
Withdrawn	`NCT02777255` - Severe CAV MRI in Heart Transplant Recipient	N/A
Completed	`NCT05373108` - Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)	Phase 4
Withdrawn	`NCT01424917` - Noninvasive Predictors of Transplant Vasculopathy	N/A
Recruiting	`NCT04770012` - AERIAL Trial: Antiplatelet Therapy in Heart Transplantation	Phase 3
Active, not recruiting	`NCT01078363` - Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy	N/A
Completed	`NCT03734211` - Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients	Phase 3
Recruiting	`NCT06089486` - MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation	N/A

NCT number	NCT04791852
Study type	Observational
Source	Puerta de Hierro University Hospital
Contact
Status	Completed
Phase
Start date	January 10, 2019
Completion date	April 15, 2021

Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy — FreeDNA-CAV

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms